Top Page
NervGen Pharma
(OTC:NGEN)
NervGen Pharma (NGEN) vs. S&P 500 (SPY)
NervGen Pharma Business Overview & Revenue Model
NervGen Pharma Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -91.96K | -145.00K | -115.11K | -42.63K | -39.65K | -38.22K | EBIT |
| -23.03M | -17.78M | -22.82M | -12.87M | -11.19M | -9.86M | EBITDA |
| -26.65M | -17.72M | -20.09M | -12.77M | -11.16M | -9.83M | Net Income Common Stockholders |
| -23.96M | -22.38M | -18.11M | -12.64M | -11.18M | -9.67M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 22.45M | 11.66M | 22.45M | 16.93M | 5.60M | 4.11M | Total Assets |
| 23.88M | 13.24M | 23.88M | 17.90M | 6.68M | 6.77M | Total Debt |
| 283.45K | 197.19K | 283.45K | 0.00 | 0.00 | 0.00 | Net Debt |
| -22.17M | -11.46M | -22.17M | -16.93M | -5.60M | -4.11M | Total Liabilities |
| 10.41M | 15.25M | 10.41M | 1.08M | 755.07K | 923.95K | Stockholders Equity |
| 13.46M | -2.01M | 13.46M | 16.82M | 5.92M | 5.84M |
| Cash Flow | Free Cash Flow | ||||
| -16.27M | -11.44M | -17.81M | -8.31M | -6.31M | -8.09M | Operating Cash Flow |
| -16.27M | -11.30M | -17.78M | -8.27M | -6.31M | -8.09M | Investing Cash Flow |
| 33.64K | -138.85K | -21.11K | -45.09K | -3.42K | 0.00 | Financing Cash Flow |
| 22.46M | 766.28K | 22.64M | 19.61M | 7.85M | 9.84M |
NervGen Pharma Technical Analysis
NervGen Pharma Peers Comparison
NervGen Pharma Corporate Events
NervGen Pharma announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, where CEO Mike Kelly will present. The company is making strides in the biotech industry with its lead candidate NVG-291, which has received FDA Fast Track designation for spinal cord injury, highlighting its potential impact on nervous system repair therapies.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma’s overall stock score reflects its position as a high-risk, high-reward biotech investment. The company’s financial health is weak, characterized by consistent losses and reliance on financing. However, positive corporate events and stable technical indicators offer potential long-term upside if clinical trials succeed.
To see Spark’s full report on TSE:NGEN stock, click here.
NervGen Pharma Corp. announced an update on its at-the-market equity program, which was launched in December 2024. During the first quarter of 2025, the company issued and sold 564,500 common shares, generating gross proceeds of $1,639,761. After deducting placement fees, the net proceeds amounted to $1,606,965. This financial maneuver is part of NervGen’s strategy to support its ongoing clinical trials and preclinical evaluations, potentially strengthening its position in the biotech industry focused on neurorestorative therapies.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma’s overall stock score reflects its position as a high-risk, high-reward biotech company. The company’s financial health is weak, characterized by consistent losses and reliance on financing. Technical indicators suggest a stable yet cautious market sentiment. Valuation remains challenging due to negative earnings, but recent clinical advancements offer potential long-term upside if successful.
To see Spark’s full report on TSE:NGEN stock, click here.
NervGen Pharma has reported its 2024 year-end financial results and business updates, highlighting significant progress in the clinical development of its lead drug candidate, NVG-291, for spinal cord injury (SCI). The company completed enrollment in the chronic cohort and began enrollment in the subacute cohort of its Phase 1b/2a clinical trial, with topline data expected in June 2025. Additionally, the FDA has approved an expanded access protocol for NVG-291, and preclinical studies of NVG-300 in ischemic stroke and SCI have shown promising results. The company plans to use proceeds from recent financing to fund ongoing research and development activities through Q3 2025.
NervGen Pharma Corp. has initiated an expanded access policy for its investigational product NVG-291, allowing individuals with spinal cord injuries who participated in its clinical trials to continue treatment. This decision follows a request from a physician and approval from the FDA to proceed with the expanded access protocol. The policy aims to provide treatment opportunities for those with unmet medical needs, while the company continues its Phase 1b/2a clinical trial to evaluate NVG-291’s efficacy and safety.
NervGen Pharma announced a virtual investor event to discuss its Phase 1b/2a clinical trial for NVG-291, a therapeutic peptide aimed at nervous system repair in spinal cord injury patients. The event will provide insights into the trial’s design and endpoints, highlighting the potential impact on spinal cord injury treatment and NervGen’s position in the biotech industry.
NervGen Pharma has granted 545,000 incentive stock options to its employees and consultants, with specific allocations to company officers and investor relations consultants. This move aligns with the company’s stock option plan and TSX Venture Exchange policies, potentially enhancing employee motivation and aligning interests with company growth objectives.
NervGen Pharma announced that its President & CEO, Mr. Mike Kelly, will present at the Virtual Life Sciences Investor Forum. This event, hosted by OTC Markets Group and VirtualInvestorConferences.com, will take place on March 13, 2025, with opportunities for virtual one-on-one investor meetings. This presentation could enhance NervGen’s visibility among investors and stakeholders, potentially impacting its market positioning positively.
NervGen Pharma announced the granting of 627,200 incentive stock options to its employees, including a significant portion to company officers. This move reflects the company’s commitment to aligning employee incentives with its growth objectives, potentially impacting its operational focus and stakeholder engagement positively.
NervGen Pharma has announced the enrollment and dosing of the first subject in the subacute cohort of its Phase 1b/2a clinical trial for NVG-291, targeting spinal cord injury. This trial evaluates the efficacy and safety of NVG-291 in both chronic and subacute cervical spinal cord injury patients. An amendment to the trial protocol, approved by the IRB, aims to enhance enrollment and improve participant experience by revising timing and reducing assessment burdens. This development marks a significant step in NervGen’s efforts to advance NVG-291, with expected data on the chronic cohort in Q2 2025, potentially positioning the company as a leader in spinal cord injury therapeutics.
NervGen Pharma announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, where CEO Mike Kelly will present on the company’s progress. NervGen is advancing its lead molecule, NVG-291, a pioneering therapeutic peptide aimed at nervous system repair, and has received Fast Track designation from the FDA for spinal cord injury. This participation at the conference highlights NervGen’s ongoing efforts to strengthen its position in the biotech industry and engage with stakeholders.